- Home
- AEON vs PASG Comparison
AEON vs PASG Comparison
Compare AEON & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | PASG |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | 8 | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.0M | 19.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | AEON | PASG |
|---|---|---|
| Price | $0.64 | $5.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $7.20 | ★ $14.00 |
| AVG Volume (30 Days) | ★ 35.6K | 35.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $0.35 |
| 52 Week High | $1.45 | $20.00 |
Technical Indicators
Market Signals| Indicator | AEON | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 32.99 | 49.11 |
| Support Level | $0.65 | $4.94 |
| Resistance Level | $1.12 | $5.90 |
| Average True Range (ATR) | 0.05 | 0.43 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 57.04 | 58.26 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications. The company is advancing ABP-450 through the biosimilar regulatory pathway and holds development and commercialization rights across multiple international markets.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.